Cutaneous Malignancies in Solid Organ Transplant Recipients

  • Amit Mittal
  • Günther F. L. Hofbauer
  • Oscar R. Colegio
Chapter

Abstract

In solid organ transplant recipients (SOTRs), long-term utilization of immunosuppressive therapy is a critical component of preventing graft rejection. Immunosuppression medications, however, inadvertently lead to decreased tumor surveillance; consequently, SOTRs represent a high-risk population for the development of malignant tumors. In particular, SOTRs are prone to developing skin cancers, which exhibit unique epidemiologic, pathophysiologic, and prognostic characteristics in this patient subset. In this chapter, we discuss the most commonly reported skin cancers in SOTRs: keratinocyte carcinomas (i.e., squamous cell carcinoma and basal cell carcinoma), Kaposi’s sarcoma, Merkel cell carcinoma, malignant melanoma, primary cutaneous posttransplantation lymphoproliferative disease (PTLD), cutaneous sarcomas, and appendageal carcinomas. Because these tumors are aggressive and tend to respond poorly to standard surgery, radiation therapy, and chemotherapy, SOTRs require patient education and motivational support, regular follow-up, and management by an interdisciplinary clinician team. Further research and clinical trials are warranted to improve treatment protocols.

Keywords

Skin cancer Squamous cell carcinoma Basal cell carcinoma Melanoma Merkel cell carcinoma 

Notes

Acknowledgement

This work was supported by a grant from the Doris Duke Charitable Foundation (15-007374) to ORC.

References

  1. 1.
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–91.CrossRefPubMedGoogle Scholar
  2. 2.
    Hiesse C, Rieu P, Kriaa F, Larue JR, Goupy C, Neyrat N, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc. 1997;29(1–2):831–3.CrossRefPubMedGoogle Scholar
  3. 3.
    Greenberg JN, Zwald FO. Management of skin cancer in solid-organ transplant recipients: a multidisciplinary approach. Dermatol Clin. 2011;29(2):231–41, ix.CrossRefPubMedGoogle Scholar
  4. 4.
    Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000;23(2):101–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Pollard JD, Hanasono MM, Mikulec AA, Le QT, Terris DJ. Head and neck cancer in cardiothoracic transplant recipients. Laryngoscope. 2000;110(8):1257–61.CrossRefPubMedGoogle Scholar
  6. 6.
    Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40(2 Pt 1):177–86.CrossRefPubMedGoogle Scholar
  7. 7.
    Wisgerhof HC, van der Boog PJ, de Fijter JW, Wolterbeek R, Haasnoot GW, Claas FH, et al. Increased risk of squamous-cell carcinoma in simultaneous pancreas kidney transplant recipients compared with kidney transplant recipients. J Invest Dermatol. 2009;129(12):2886–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Rashtak S, Dierkhising RA, Kremers WK, Peters SG, Cassivi SD, Otley CC. Incidence and risk factors for skin cancer following lung transplantation. J Am Acad Dermatol. 2015;72(1):92–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Perera GK, Child FJ, Heaton N, O'Grady J, Higgins EM. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol. 2006;154(5):868–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepato-Gastroenterology. 1997;44(16):1172–81.PubMedGoogle Scholar
  11. 11.
    Kelly DM, Emre S, Guy SR, Miller CM, Schwartz ME, Sheiner PA. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer. 1998;83(6):1237–43.CrossRefPubMedGoogle Scholar
  12. 12.
    Levy M, Backman L, Husberg B, Goldstein R, McMillan R, Gibbs J, et al. De novo malignancy following liver transplantation: a single-center study. Transplant Proc. 1993;25(1 Pt 2):1397–9.PubMedGoogle Scholar
  13. 13.
    Bouwes Bavinck JN, Euvrard S, Naldi L, Nindl I, Proby CM, Neale R, et al. Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol. 2007;127(7):1647–56.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol. 2003;49(3):397–406.CrossRefPubMedGoogle Scholar
  15. 15.
    Moloney FJ, Comber H, O'Lorcain P, O’Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. 2006;154(3):498–504.CrossRefPubMedGoogle Scholar
  16. 16.
    Krynitz B, Olsson H, Lundh Rozell B, Lindelof B, Edgren G, Smedby KE. Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study. Br J Dermatol. 2016;174(1):95–103.CrossRefPubMedGoogle Scholar
  17. 17.
    Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):253–61; quiz 262.CrossRefPubMedGoogle Scholar
  18. 18.
    Hardie IR, Strong RW, Hartley LC, Woodruff PW, Clunie GJ. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery. 1980;87(2):177–83.PubMedGoogle Scholar
  19. 19.
    Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol. 2002;147(5):950–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Chockalingam R, Downing C, Tyring SK. Cutaneous squamous cell carcinomas in organ transplant recipients. J Clin Med. 2015;4(6):1229–39.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol. 2001;27(4):409–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Carucci JA, Martinez JC, Zeitouni NC, Christenson L, Coldiron B, Zweibel S, et al. In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg. 2004;30(4 Pt 2):651–5.PubMedGoogle Scholar
  23. 23.
    Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation. 1996;61(5):715–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Ulrich C, Schmook T, Sachse MM, Sterry W, Stockfleth E. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg. 2004;30(4 Pt 2):622–7.PubMedGoogle Scholar
  25. 25.
    Fortina AB, Caforio AL, Piaserico S, Alaibac M, Tona F, Feltrin G, et al. Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant. 2000;19(3):249–55.CrossRefPubMedGoogle Scholar
  26. 26.
    Otley CC, Cherikh WS, Salasche SJ, McBride MA, Christenson LJ, Kauffman HM. Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol. 2005;53(5):783–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients—where do we stand today? Am J Transplant. 2008;8(11):2192–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Ramsay HM, Reece SM, Fryer AA, Smith AG, Harden PN. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation. 2007;84(3):437–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation. 2004;77(4):574–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Espana A, Martinez-Gonzalez MA, Garcia-Granero M, Sanchez-Carpintero I, Rabago G, Herreros J. A prospective study of incident nonmelanoma skin cancer in heart transplant recipients. J Invest Dermatol. 2000;115(6):1158–60.CrossRefPubMedGoogle Scholar
  31. 31.
    Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years’ experience at a single centre. Transplant Proc. 1997;29(1–2):828–30.CrossRefPubMedGoogle Scholar
  32. 32.
    Liddington M, Richardson AJ, Higgins RM, Endre ZH, Venning VA, Murie JA, et al. Skin cancer in renal transplant recipients. Br J Surg. 1989;76(10):1002–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Brewer JD, Colegio OR, Phillips PK, Roenigk RK, Jacobs MA, Van de Beek D, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol. 2009;145(12):1391–6.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Einollahi B, Nemati E, Lessan-Pezeshki M, Simforoosh N, Nourbala MH, Rostami Z, et al. Skin cancer after renal transplantation: results of a multicenter study in Iran. Ann Transplant. 2010;15(3):44–50.PubMedGoogle Scholar
  35. 35.
    Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet. 1997;349(9049):398.CrossRefPubMedGoogle Scholar
  36. 36.
    Salgo R, Gossmann J, Schofer H, Kachel HG, Kuck J, Geiger H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10(6):1385–93.CrossRefPubMedGoogle Scholar
  37. 37.
    Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367(4):329–39.CrossRefPubMedGoogle Scholar
  38. 38.
    Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012;12(5):1146–56.CrossRefPubMedGoogle Scholar
  39. 39.
    Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349:g6679.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Karia PS, Azzi JR, Heher EC, Hills VM, Schmults CD. Association of sirolimus use with risk for skin cancer in a mixed-organ cohort of solid-organ transplant recipients with a history of cancer. JAMA Dermatol. 2016;152(5):533–40.CrossRefPubMedGoogle Scholar
  41. 41.
    Kim C, Cheng J, Colegio OR. Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment. Semin Oncol. 2016;43(3):390–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Mansh M, Binstock M, Williams K, Hafeez F, Kim J, Glidden D, et al. Voriconazole exposure and risk of cutaneous squamous cell carcinoma, aspergillus colonization, invasive aspergillosis and death in lung transplant recipients. Am J Transplant. 2016;16(1):262–70.CrossRefPubMedGoogle Scholar
  43. 43.
    Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014;58(7):997–1002.CrossRefPubMedGoogle Scholar
  44. 44.
    Yu SH, Bordeaux JS, Baron ED. The immune system and skin cancer. Adv Exp Med Biol. 2014;810:182–91.PubMedGoogle Scholar
  45. 45.
    Aubin F. Mechanisms involved in ultraviolet light-induced immunosuppression. Eur J Dermatol. 2003;13(6):515–23.PubMedGoogle Scholar
  46. 46.
    Nindl I, Gottschling M, Stockfleth E. Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers. 2007;23(4):247–59.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Connolly K, Manders P, Earls P, Epstein RJ. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one notch closer to control. Cancer Treat Rev. 2014;40(2):205–14.CrossRefPubMedGoogle Scholar
  48. 48.
    Neale RE, Weissenborn S, Abeni D, Bavinck JN, Euvrard S, Feltkamp MC, et al. Human papillomavirus load in eyebrow hair follicles and risk of cutaneous squamous cell carcinoma. Cancer Epidemiol Biomark Prev. 2013;22(4):719–27.CrossRefGoogle Scholar
  49. 49.
    Reuschenbach M, Tran T, Faulstich F, Hartschuh W, Vinokurova S, Kloor M, et al. High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients. Br J Cancer. 2011;104(8):1334–41.PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Athar M, Walsh SB, Kopelovich L, Elmets CA. Pathogenesis of nonmelanoma skin cancers in organ transplant recipients. Arch Biochem Biophys. 2011;508(2):159–63.PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.
    Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol. 2011;131(8):1745–53.PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Wu X, Nguyen BC, Dziunycz P, Chang S, Brooks Y, Lefort K, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature. 2010;465(7296):368–72.PubMedCentralCrossRefPubMedGoogle Scholar
  53. 53.
    Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–4.CrossRefPubMedGoogle Scholar
  54. 54.
    Walsh SB, Xu J, Xu H, Kurundkar AR, Maheshwari A, Grizzle WE, et al. Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGF beta signaling pathway. Mol Carcinog. 2011;50(7):516–27.PubMedCentralCrossRefPubMedGoogle Scholar
  55. 55.
    Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation. 1987;44(3):429–34.CrossRefPubMedGoogle Scholar
  56. 56.
    Brem R, Li F, Karran P. Reactive oxygen species generated by thiopurine/UVA cause irreparable transcription-blocking DNA lesions. Nucleic Acids Res. 2009;37(6):1951–61.PubMedCentralCrossRefPubMedGoogle Scholar
  57. 57.
    Zhang X, Jeffs G, Ren X, O'Donovan P, Montaner B, Perrett CM, et al. Novel DNA lesions generated by the interaction between therapeutic thiopurines and UVA light. DNA Repair (Amst). 2007;6(3):344–54.CrossRefGoogle Scholar
  58. 58.
    Ren X, Xu YZ, Karran P. Photo-oxidation of 6-thioguanine by UVA: the formation of addition products with low molecular weight thiol compounds. Photochem Photobiol. 2010;86(5):1038–45.CrossRefPubMedGoogle Scholar
  59. 59.
    Burt A, Abramov Iu B, Sachkov VI. Is fluidization of the phospholipid bilayer by general anesthetics a reason for general anesthesia? Biull Eksp Biol Med. 1991;112(10):387–9.PubMedGoogle Scholar
  60. 60.
    Urwin HR, Jones PW, Harden PN, Ramsay HM, Hawley CM, Nicol DL, et al. Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. Transplantation. 2009;87(11):1667–71.CrossRefPubMedGoogle Scholar
  61. 61.
    Stasko T, Brown MD, Carucci JA, Euvrard S, Johnson TM, Sengelmann RD, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):642–50.PubMedGoogle Scholar
  62. 62.
    Bangash HK, Colegio OR. Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients. Curr Treat Options in Oncol. 2012;13(3):354–76.CrossRefGoogle Scholar
  63. 63.
    Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1–17; quiz 18-20.CrossRefPubMedGoogle Scholar
  64. 64.
    Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis. 2000;36(1):167–76.CrossRefPubMedGoogle Scholar
  65. 65.
    Jiyad Z, Marquart L, O'Rourke P, Green AC. The natural history of actinic keratoses in organ transplant recipients. J Am Acad Dermatol. 2017;76(1):162–4.CrossRefPubMedGoogle Scholar
  66. 66.
    Ingham AI, Weightman W. The efficacy and safety of topical 5% 5-fluorouracil in renal transplant recipients for the treatment of actinic keratoses. Australas J Dermatol. 2014;55(3):204–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Trakatelli M, Katsanos G, Ulrich C, Kalabalikis D, Sotiriadis D, Stockfleth E. Efforts to counteract locally the effects of systemic immunosupression: a review on the use of imiquimod, a topical immunostimulator in organ transplant recipients. Int J Immunopathol Pharmacol. 2010;23(2):387–96.CrossRefPubMedGoogle Scholar
  68. 68.
    Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PC, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157(Suppl 2):25–31.PubMedCentralCrossRefPubMedGoogle Scholar
  69. 69.
    Ulrich C, Busch JO, Meyer T, Nindl I, Schmook T, Sterry W, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol. 2006;155(2):451–4.CrossRefPubMedGoogle Scholar
  70. 70.
    Santos-Juanes J, Esteve A, Mas-Vidal A, Coto-Segura P, Salgueiro E, Gomez E, et al. Acute renal failure caused by imiquimod 5% cream in a renal transplant patient: review of the literature on side effects of imiquimod. Dermatology. 2011;222(2):109–12.CrossRefPubMedGoogle Scholar
  71. 71.
    Lonsdorf AS, Becker MR, Stockfleth E, Schakel K, Ulrich C. Primary and secondary prevention of skin cancer in organ transplant recipients. Hautarzt. 2010;61(3):195–206.CrossRefPubMedGoogle Scholar
  72. 72.
    Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, Sterry W, Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol. 2010;20(4):482–8.PubMedGoogle Scholar
  73. 73.
    Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66(3):486–93.CrossRefPubMedGoogle Scholar
  74. 74.
    Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16–22.CrossRefPubMedGoogle Scholar
  75. 75.
    Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010–9.CrossRefPubMedGoogle Scholar
  76. 76.
    Mohanna M, Hofbauer G. Pronounced local skin reaction to ingenol mebutate against actinic keratosis in kidney transplant recipient without systemic adverse events. JAAD Case Rep. 2015;1(6):S19–22.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    Dragieva G, Hafner J, Dummer R, Schmid-Grendelmeier P, Roos M, Prinz BM, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipients. Transplantation. 2004;77(1):115–21.CrossRefPubMedGoogle Scholar
  78. 78.
    Piaserico S, Belloni Fortina A, Rigotti P, Rossi B, Baldan N, Alaibac M, et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc. 2007;39(6):1847–50.CrossRefPubMedGoogle Scholar
  79. 79.
    Wlodek C, Ali FR, Lear JT. Use of photodynamic therapy for treatment of actinic keratoses in organ transplant recipients. Biomed Res Int. 2013;2013:349526.CrossRefPubMedGoogle Scholar
  80. 80.
    Togsverd-Bo K, Omland SH, Wulf HC, Sorensen SS, Haedersdal M. Primary prevention of skin dysplasia in renal transplant recipients with photodynamic therapy: a randomized controlled trial. Am J Transplant. 2015;15(11):2986–90.CrossRefPubMedGoogle Scholar
  81. 81.
    Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975–83.CrossRefPubMedGoogle Scholar
  82. 82.
    Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):263–79; quiz 280.CrossRefPubMedGoogle Scholar
  83. 83.
    Locke J, Karimpour S, Young G, Lockett MA, Perez CA. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):748–55.CrossRefPubMedGoogle Scholar
  84. 84.
    Koyfman SA, Joshi N, Vidimos A. Adjuvant radiotherapy in high-risk cutaneous squamous cell cancer of the head and neck in immunosuppressed patients. JAAD Case Rep. 2015;1(6):S5–7.PubMedCentralCrossRefPubMedGoogle Scholar
  85. 85.
    Veness MJ, Quinn DI, Ong CS, Keogh AM, Macdonald PS, Cooper SG, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer. 1999;85(8):1758–64.CrossRefPubMedGoogle Scholar
  86. 86.
    Manyam BV, Gastman B, Zhang AY, Reddy CA, Burkey BB, Scharpf J, et al. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy. J Am Acad Dermatol. 2015;73(2):221–7.CrossRefPubMedGoogle Scholar
  87. 87.
    Kyrgidis A, Tzellos TG, Kechagias N, Patrikidou A, Xirou P, Kitikidou K, et al. Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer. 2010;46(9):1563–72.CrossRefPubMedGoogle Scholar
  88. 88.
    Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014;32(4):327–34.CrossRefPubMedGoogle Scholar
  89. 89.
    Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, Hwang WT, Gelfand JM, Whalen FM, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149(4):402–10.CrossRefPubMedGoogle Scholar
  90. 90.
    Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol. 2014;150(1):19–24.CrossRefPubMedGoogle Scholar
  91. 91.
    Allen JE, Stolle LB. Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol. 2015;41(2):197–200.CrossRefPubMedGoogle Scholar
  92. 92.
    Samsanavicius D, Kaikaris V, Norvydas SJ, Liubauskas R, Valiukeviciene S, Makstiene J, et al. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: analysis of recurrence-free survival. Medicina (Kaunas). 2016;52(5):276–82.CrossRefGoogle Scholar
  93. 93.
    Krediet JT, Beyer M, Lenz K, Ulrich C, Lange-Asschenfeldt B, Stockfleth E, et al. Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. Br J Dermatol. 2015;172(4):1029–36.CrossRefPubMedGoogle Scholar
  94. 94.
    Matthey-Gie ML, Boubaker A, Letovanec I, Demartines N, Matter M. Sentinel lymph node biopsy in nonmelanoma skin cancer patients. J Skin Cancer. 2013;2013:267474.PubMedCentralCrossRefPubMedGoogle Scholar
  95. 95.
    Ruiz ES, Karia PS, Morgan FC, Schmults CD. The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol. 2017;76(2):217–25.CrossRefPubMedGoogle Scholar
  96. 96.
    Otley CC, Berg D, Ulrich C, Stasko T, Murphy GM, Salasche SJ, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol. 2006;154(3):395–400.CrossRefPubMedGoogle Scholar
  97. 97.
    Colegio OR, Hanlon A, Olasz EB, Carucci JA. Sirolimus reduces cutaneous squamous cell carcinomas in transplantation recipients. J Clin Oncol. 2013;31(26):3297–8.CrossRefPubMedGoogle Scholar
  98. 98.
    George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol. 2002;43(4):269–73.CrossRefPubMedGoogle Scholar
  99. 99.
    Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol. 2005;141(4):456–64.CrossRefPubMedGoogle Scholar
  100. 100.
    Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, Dudek AZ. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transpl. 2011;25(4):541–8.CrossRefGoogle Scholar
  101. 101.
    Endrizzi B, Ahmed RL, Ray T, Dudek A, Lee P. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. Dermatol Surg. 2013;39(4):634–45.CrossRefPubMedGoogle Scholar
  102. 102.
    Shao XH, Xu YS, Zhang XQ, Li WF. Evidence based analysis of Cisplatin for treating patients with cutaneous squamous cell carcinoma. Asian Pac J Cancer Prev. 2014;15(22):9813–5.CrossRefPubMedGoogle Scholar
  103. 103.
    Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer. 1991;67(8):2030–2.CrossRefPubMedGoogle Scholar
  104. 104.
    Boyd K, Shea SM, Patterson J. Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients. Wien Med Wochenschr. 2013;163(15–16):372–5.CrossRefPubMedGoogle Scholar
  105. 105.
    Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quereux G, et al. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat. 2014;25(5):424–7.CrossRefPubMedGoogle Scholar
  106. 106.
    Leard LE, Cho BK, Jones KD, Hays SR, Tope WD, Golden JA, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant. 2007;26(12):1340–4.CrossRefPubMedGoogle Scholar
  107. 107.
    Slater NA, Googe PB. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. J Cutan Pathol. 2016;43(8):663–70.CrossRefPubMedGoogle Scholar
  108. 108.
    Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016;4:70.PubMedCentralCrossRefPubMedGoogle Scholar
  109. 109.
    Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374(9):896–8.PubMedCentralCrossRefPubMedGoogle Scholar
  110. 110.
    Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32(19):e69–71.PubMedCentralCrossRefPubMedGoogle Scholar
  111. 111.
    Perkins JL, Liu Y, Mitby PA, Neglia JP, Hammond S, Stovall M, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2005;23(16):3733–41.CrossRefPubMedGoogle Scholar
  112. 112.
    Karagas MR, Nelson HH, Zens MS, Linet M, Stukel TA, Spencer S, et al. Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology. 2007;18(6):776–84.CrossRefPubMedGoogle Scholar
  113. 113.
    Watt TC, Inskip PD, Stratton K, Smith SA, Kry SF, Sigurdson AJ, et al. Radiation-related risk of basal cell carcinoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2012;104(16):1240–50.PubMedCentralCrossRefPubMedGoogle Scholar
  114. 114.
    Lichter MD, Karagas MR, Mott LA, Spencer SK, Stukel TA, Greenberg ER. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol. 2000;136(8):1007–11.CrossRefPubMedGoogle Scholar
  115. 115.
    Epstein EH Jr. Mommy—where do tumors come from? J Clin Invest. 2011;121(5):1681–3.PubMedCentralCrossRefPubMedGoogle Scholar
  116. 116.
    Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021–6. e1028.CrossRefPubMedGoogle Scholar
  117. 117.
    Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):904–11. e901.CrossRefPubMedGoogle Scholar
  118. 118.
    Cusack CA, Nijhawan R, Miller B, Henien M, Malat G, Doyle A, et al. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient. JAMA Dermatol. 2015;151(1):70–2.CrossRefPubMedGoogle Scholar
  119. 119.
    Markowitz O, Schwartz M. The use of noninvasive optical coherence tomography to monitor the treatment progress of vismodegib and imiquimod 5% cream in a transplant patient with advanced basal cell carcinoma of the nose. J Clin Aesthet Dermatol. 2016;9(8):37–41.PubMedCentralPubMedGoogle Scholar
  120. 120.
    Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell. 2006;10(2):133–43.CrossRefPubMedGoogle Scholar
  121. 121.
    Campistol JM, Schena FP. Kaposi’s sarcoma in renal transplant recipients—the impact of proliferation signal inhibitors. Nephrol Dial Transplant. 2007;22(Suppl 1):i17–22.CrossRefPubMedGoogle Scholar
  122. 122.
    Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation. 2004;77(5):760–2.CrossRefPubMedGoogle Scholar
  123. 123.
    Harwood AR, Osoba D, Hofstader SL, Goldstein MB, Cardella CJ, Holecek MJ, et al. Kaposi’s sarcoma in recipients of renal transplants. Am J Med. 1979;67(5):759–65.CrossRefPubMedGoogle Scholar
  124. 124.
    Woodle ES, Hanaway M, Buell J, Gross T, First MR, Trofe J, et al. Kaposi sarcoma: an analysis of the US and international experiences from the Israel Penn International Transplant Tumor Registry. Transplant Proc. 2001;33(7–8):3660–1.CrossRefPubMedGoogle Scholar
  125. 125.
    Zavos G, Moris D, Vernadakis S, Bokos J, Lionaki S, Mamarelis G, et al. Incidence and management of Kaposi sarcoma in renal transplant recipients: the Greek experience. Transplant Proc. 2014;46(9):3199–202.CrossRefPubMedGoogle Scholar
  126. 126.
    Gorsane I, Bacha MM, Abderrahim E, Amri N, Hajri M, Ounissi M, et al. Post kidney transplantation Kaposi's sarcoma: the experience of a Mediterranean North African center. Clin Transpl. 2016;30(4):372–9.CrossRefGoogle Scholar
  127. 127.
    Cattani P, Capuano M, Graffeo R, Ricci R, Cerimele F, Cerimele D, et al. Kaposi’s sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients. J Clin Microbiol. 2001;39(2):506–8.PubMedCentralCrossRefPubMedGoogle Scholar
  128. 128.
    Frances C, Mouquet C, Marcelin AG, Barete S, Agher R, Charron D, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation. 2000;69(9):1776–9.CrossRefPubMedGoogle Scholar
  129. 129.
    Emond JP, Marcelin AG, Dorent R, Milliancourt C, Dupin N, Frances C, et al. Kaposi’s sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients. J Clin Microbiol. 2002;40(6):2217–9.PubMedCentralCrossRefPubMedGoogle Scholar
  130. 130.
    Allen UD. Human herpesvirus type 8 infections among solid organ transplant recipients. Pediatr Transplant. 2002;6(3):187–92.CrossRefPubMedGoogle Scholar
  131. 131.
    Regamey N, Tamm M, Wernli M, Witschi A, Thiel G, Cathomas G, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med. 1998;339(19):1358–63.CrossRefPubMedGoogle Scholar
  132. 132.
    Hernandez-Sierra A, Rovira J, Petit A, Moya-Rull D, Mazuecos MA, Sanchez-Fructuoso AI, et al. Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging. Transpl Int. 2016;29(9):1008–16.CrossRefPubMedGoogle Scholar
  133. 133.
    Clarke CA, Robbins HA, Tatalovich Z, Lynch CF, Pawlish KS, Finch JL et al. Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst. 2015;107(2).Google Scholar
  134. 134.
    Penn I, First MR. Merkel’s cell carcinoma in organ recipients: report of 41 cases. Transplantation. 1999;68(11):1717–21.CrossRefPubMedGoogle Scholar
  135. 135.
    Arron ST, Canavan T, Yu SS. Organ transplant recipients with Merkel cell carcinoma have reduced progression-free, overall, and disease-specific survival independent of stage at presentation. J Am Acad Dermatol. 2014;71(4):684–90.CrossRefPubMedGoogle Scholar
  136. 136.
    Siva S, Byrne K, Seel M, Bressel M, Jacobs D, Callahan J, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience. J Nucl Med. 2013;54(8):1223–9.CrossRefPubMedGoogle Scholar
  137. 137.
    Iyer JG, Storer BE, Paulson KG, Lemos B, Phillips JL, Bichakjian CK, et al. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol. 2014;70(4):637–43.PubMedCentralCrossRefPubMedGoogle Scholar
  138. 138.
    Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63(5):751–61.PubMedCentralCrossRefPubMedGoogle Scholar
  139. 139.
    Grotz TE, Joseph RW, Pockaj BA, Foote RL, Otley CC, Bagaria SP, et al. Negative sentinel lymph node biopsy in Merkel cell carcinoma is associated with a low risk of same-nodal-basin recurrences. Ann Surg Oncol. 2015;22(12):4060–6.CrossRefPubMedGoogle Scholar
  140. 140.
    Bichakjian CK, Lowe L, Lao CD, Sandler HM, Bradford CR, Johnson TM, et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer. 2007;110(1):1–12.CrossRefPubMedGoogle Scholar
  141. 141.
    Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54–63.CrossRefPubMedGoogle Scholar
  142. 142.
    Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–52.PubMedCentralCrossRefPubMedGoogle Scholar
  143. 143.
    Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br J Dermatol. 2006;154(3):472–7.CrossRefPubMedGoogle Scholar
  144. 144.
    Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–901.PubMedCentralCrossRefPubMedGoogle Scholar
  145. 145.
    Ali FR, Lear JT. Melanoma in organ transplant recipients: incidence, outcomes and management considerations. J Skin Cancer. 2012;2012:404615.PubMedCentralCrossRefPubMedGoogle Scholar
  146. 146.
    Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143(3):513–9.PubMedGoogle Scholar
  147. 147.
    Green AC, Olsen CM. Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies. Acta Derm Venereol. 2015;95(8):923–7.CrossRefPubMedGoogle Scholar
  148. 148.
    Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant. 1998;2(1):56–63.PubMedGoogle Scholar
  149. 149.
    Garrett GL, Lowenstein SE, Singer JP, He SY, Arron ST. Trends of skin cancer mortality after transplantation in the United States: 1987 to 2013. J Am Acad Dermatol. 2016;75(1):106–12.CrossRefPubMedGoogle Scholar
  150. 150.
    Robbins HA, Clarke CA, Arron ST, Tatalovich Z, Kahn AR, Hernandez BY, et al. Melanoma risk and survival among organ transplant recipients. J Invest Dermatol. 2015;135(11):2657–65.PubMedCentralCrossRefPubMedGoogle Scholar
  151. 151.
    Brewer JD, Christenson LJ, Weaver AL, Dapprich DC, Weenig RH, Lim KK, et al. Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol. 2011;147(7):790–6.CrossRefPubMedGoogle Scholar
  152. 152.
    Pavri SN, Clune J, Ariyan S, Narayan D. Malignant melanoma: beyond the basics. Plast Reconstr Surg. 2016;138(2):330e–40e.CrossRefPubMedGoogle Scholar
  153. 153.
    van Akkooi AC, Atkins MB, Agarwala SS, Lorigan P. Surgical management and adjuvant therapy for high-risk and metastatic melanoma. Am Soc Clin Oncol Educ Book. 2016;35:e505–14.CrossRefPubMedGoogle Scholar
  154. 154.
    Sladden M, Zagarella S, Popescu C, Bigby M. No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report. Br J Dermatol. 2015;172(3):566–71.CrossRefPubMedGoogle Scholar
  155. 155.
    Garrett GL, He SY, Sabouni N, Daud A, Arron ST. Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: case report and review of the literature. JAAD Case Rep. 2015;1(6):S23–5.PubMedCentralCrossRefPubMedGoogle Scholar
  156. 156.
    Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27(6):1135–7.CrossRefPubMedGoogle Scholar
  157. 157.
    Alhamad T, Venkatachalam K, Linette GP, Brennan DC. Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant. 2016;16(4):1332–3.CrossRefPubMedGoogle Scholar
  158. 158.
    Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother. 2015;38(5):211.CrossRefPubMedGoogle Scholar
  159. 159.
    Herz S, Hofer T, Papapanagiotou M, Leyh JC, Meyenburg S, Schadendorf D, et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer. 2016;67:66–72.CrossRefPubMedGoogle Scholar
  160. 160.
    Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45(2):160–9.CrossRefPubMedGoogle Scholar
  161. 161.
    Belliere J, Meyer N, Mazieres J, Ollier S, Boulinguez S, Delas A, et al. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016;115(12):1457–61.PubMedCentralCrossRefPubMedGoogle Scholar
  162. 162.
    Murakami N, Borges TJ, Yamashita M, Riella LV. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9(3):411–7.PubMedCentralCrossRefPubMedGoogle Scholar
  163. 163.
    Arron ST, Raymond AK, Yanik EL, Castenson D, McCulloch CE, Clarke CA, et al. Melanoma outcomes in transplant recipients with pretransplant melanoma. Dermatol Surg. 2016;42(2):157–66.CrossRefPubMedGoogle Scholar
  164. 164.
    Penn I. Malignant melanoma in organ allograft recipients. Transplantation. 1996;61(2):274–8.CrossRefPubMedGoogle Scholar
  165. 165.
    Matin RN, Mesher D, Proby CM, McGregor JM, Bouwes Bavinck JN, del Marmol V, et al. Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant. 2008;8(9):1891–900.CrossRefPubMedGoogle Scholar
  166. 166.
    Colegio OR, Proby CM, Bordeaux JS, McGregor JM, Melanoma Working Group of the International Transplant Skin Cancer C, Skin Care in Organ Transplant Patients E. Prognosis of pretransplant melanoma. Am J Transplant. 2009;9(4):862.CrossRefPubMedGoogle Scholar
  167. 167.
    Dapprich DC, Weenig RH, Rohlinger AL, Weaver AL, Quan KK, Keeling JH, et al. Outcomes of melanoma in recipients of solid organ transplant. J Am Acad Dermatol. 2008;59(3):405–17.CrossRefPubMedGoogle Scholar
  168. 168.
    Zwald F, Leitenberger J, Zeitouni N, Soon S, Brewer J, Arron S, et al. Recommendations for Solid Organ Transplantation for Transplant Candidates with a Pretransplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: a consensus opinion from the International Transplant Skin Cancer Collaborative (ITSCC). Am J Transplant. 2016;16(2):407–13.CrossRefPubMedGoogle Scholar
  169. 169.
    Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation. 2002;74(10):1409–13.CrossRefPubMedGoogle Scholar
  170. 170.
    Fairman RM, Grossman RA, Barker CF, Perloff LJ. Inadvertent transplantation of a melanoma. Transplantation. 1980;30(5):328–30.CrossRefPubMedGoogle Scholar
  171. 171.
    Milton CA, Barbara J, Cooper J, Rao M, Russell C, Russ G. The transmission of donor-derived malignant melanoma to a renal allograft recipient. Clin Transpl. 2006;20(5):547–50.CrossRefGoogle Scholar
  172. 172.
    Penn I. Transmission of cancer from organ donors. Ann Transplant. 1997;2(4):7–12.PubMedGoogle Scholar
  173. 173.
    Zwald FO, Christenson LJ, Billingsley EM, Zeitouni NC, Ratner D, Bordeaux J, et al. Melanoma in solid organ transplant recipients. Am J Transplant. 2010;10(5):1297–304.CrossRefPubMedGoogle Scholar
  174. 174.
    Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol. 2005;125(5):1020–5.CrossRefPubMedGoogle Scholar
  175. 175.
    Seckin D, Barete S, Euvrard S, Frances C, Kanitakis J, Geusau A, et al. Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series. Am J Transplant. 2013;13(8):2146–53.CrossRefPubMedGoogle Scholar
  176. 176.
    Kempf W, Mertz KD, Hofbauer GF, Tinguely M. Skin cancer in organ transplant recipients. Pathobiology. 2013;80(6):302–9.CrossRefPubMedGoogle Scholar
  177. 177.
    Llaurador G, McLaughlin L, Wistinghausen B. Management of post-transplant lymphoproliferative disorders. Curr Opin Pediatr. 2017;29(1):34–40.CrossRefPubMedGoogle Scholar
  178. 178.
    Webster P, Wujanto L, Fisher C, Walker M, Ramakrishnan R, Naresh K, et al. Malignancies confined to disused arteriovenous fistulae in renal transplant patients: an important differential diagnosis. Am J Nephrol. 2011;34(1):42–8.CrossRefPubMedGoogle Scholar
  179. 179.
    Baer LN, Savage DG, Hibshoosh HH, Kalinsky K. Concomitant angiosarcoma and lymphoproliferative disorder in solid organ transplant recipients. Clin Sarcoma Res. 2014;4(1):15.PubMedCentralCrossRefPubMedGoogle Scholar
  180. 180.
    Lopez L, Velez R. Atypical fibroxanthoma. Arch Pathol Lab Med. 2016;140(4):376–9.CrossRefPubMedGoogle Scholar
  181. 181.
    McCoppin HH, Christiansen D, Stasko T, Washington C, Martinez JC, Brown MD, et al. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience. Dermatol Surg. 2012;38(2):230–9.CrossRefPubMedGoogle Scholar
  182. 182.
    Giuffrida TJ, Kligora CJ, Goldstein GD. Localized cutaneous metastases from an atypical fibroxanthoma. Dermatol Surg. 2004;30(12 Pt 2):1561–4.PubMedGoogle Scholar
  183. 183.
    Lai KN, Lai FM, King WW, Li PK, Siu D, Leung CB, et al. Dermatofibrosarcoma protuberans in a renal transplant patient. Aust N Z J Surg. 1995;65(12):900–2.CrossRefPubMedGoogle Scholar
  184. 184.
    Harwood CA, McGregor JM, Swale VJ, Proby CM, Leigh IM, Newton R, et al. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol. 2003;48(3):401–8.CrossRefPubMedGoogle Scholar
  185. 185.
    Lanoy E, Costagliola D, Engels EA. Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. Int J Cancer. 2010;126(7):1724–31.PubMedCentralPubMedGoogle Scholar
  186. 186.
    Harwood CA, Swale VJ, Bataille VA, Quinn AG, Ghali L, Patel SV, et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol. 2001;116(2):246–53.CrossRefPubMedGoogle Scholar
  187. 187.
    Mittal A, Colegio OR. Skin cancers in organ transplant recipients. Am J Transplant. 2017;17(10):2509–30.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Amit Mittal
    • 1
  • Günther F. L. Hofbauer
    • 2
  • Oscar R. Colegio
    • 3
  1. 1.Department of DermatologyYale University School of MedicineNew HavenUSA
  2. 2.Service of Internal Medicine and Nephrology Hirslanden HospitalZürichSwitzerland
  3. 3.Department of DermatologyYale School of MedicineNew HavenUSA

Personalised recommendations